Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mind and body: does resilience leave a molecular mark in breast cancer?

NCT ID NCT03430492

Knowledge-focused Sponsor: Lund University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Researchers at Lund University are studying whether psychological resilience, a person's ability to cope with stress, is linked to biological markers in breast cancer patients. They will measure resilience through questionnaires and analyze tumor and blood samples for molecular signatures. The study follows nearly 1,000 newly diagnosed patients to see if resilience relates to quality of life and prognosis over time. The goal is to understand if mental state might influence disease biology and open new avenues for supportive care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If resilience links to specific molecular patterns, it could open new ways to support patients through medical and psychosocial care.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not lead to direct treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

985 people

The number who actually took part.

Started

Feb 2016

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

SCAN-B Resilience is, as a part of the SCAN-B program, a prospective breast cancer study with established infrastructure for enrollment and follow-ups for patient. The study population is newly diagnosed breast cancer patients enrolled in SCAN-B at the hospitals in Karlskrona, Helsingborg, Växjö and Halmstad. The INCA register (a information network for cancer care) includes almost 100% of all women diagnosed with breast cancer. Based on comparison with cancer registrations in INCA for 2011-2012, 85 % of all new breast cancer diagnosed women are included in SCAN-B. In April 2017 83% of patients included in SCAN-B were also enrolled in SCAN-B Resilience why a majority (70%) of women diagnosed with breast cancer are enrolled in this study

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed patients with primary breast cancer * Patients consented to be included in the SCAN-B study at (Blekinge County Hospital, Central Hospital Växjö and Hallands Hospital Halmstad HBG?? * Oral and written consent for the SCAN-B Resilience study * Age ≥ 18 years * Patients that do understand the Swedish language (written and spoken) Exclusion Criteria: * No diagnosis of breast cancer * Not consented to be included in the SCAN-B study * Do not understand the Swedish language

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Blekinge County Hospital

    Karlskrona, Blekinge County, 37480, Sweden

  • Central Hospital Växjö

    Vaxjo, Småland, 35185, Sweden

  • Hallands Hospital Halmstad

    Halmstad, Halland County, 30185, Sweden

  • Helsingborgs hospital

    Helsingborg, Skåne County, 25187, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.